Heart Disease Trial, Recruiting NCT05714241 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05714241
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who have been diagnosed with INOCA (a condition where the heart does not get enough blood flow, but no blockages are found in the main heart arteries)
  • People who are currently taking low-dose aspirin (100 mg daily by mouth for more than 3 days, or who recently received a higher dose of aspirin through a drip followed by 100 mg daily by mouth)

Who may not be able to join:

  • People who are currently taking or have recently taken certain blood-thinning or clot-dissolving medications, including clot-busting drugs, certain injectable blood thinners that work on platelets, blood thinners taken by mouth, or a class of medications called thienopyridines
  • People whose platelet count (a blood measurement related to clotting) falls outside the range of 125–450 (×10⁹/L) (confirm with trial site)
  • People with other serious health conditions where life expectancy is estimated to be less than one year
  • People who have a known allergy or sensitivity to the medications used in this trial, or to any of their ingredients
  • People with significant kidney or liver disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rocco A Montone, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phone: +39-0630154187

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 February 2022
Est. completion
1 March 2025

Where this trial is recruiting

🇮🇹 Italy 🇪🇸 Spain

Primary endpoints

Biomarker, miRNA and platelet function assessment for the specific endotype of INOCA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov